GILD · Categories · Upgrades
GILD - Analyst upgrades
Gilead Sciences Inc. (GILD) analyst upgrades - real-time wire coverage filtered to Upgrades only.
Recent Upgrades for GILD
- Gilead Sciences upgraded by Maxim Group with a new price targetMaxim Group upgraded Gilead Sciences from Hold to Buy and set a new price target of $165.00
- Gilead Sciences upgraded by Daiwa Securities with a new price targetDaiwa Securities upgraded Gilead Sciences from Neutral to Outperform and set a new price target of $128.00
- Gilead Sciences upgraded by Truist with a new price targetTruist upgraded Gilead Sciences from Hold to Buy and set a new price target of $127.00
- Gilead Sciences upgraded by Needham with a new price targetNeedham upgraded Gilead Sciences from Hold to Buy and set a new price target of $133.00
- Gilead Sciences upgraded by Deutsche Bank with a new price targetDeutsche Bank upgraded Gilead Sciences from Hold to Buy and set a new price target of $120.00
- Gilead Sciences upgraded by DZ Bank with a new price targetDZ Bank upgraded Gilead Sciences from Hold to Buy and set a new price target of $108.00
- Gilead Sciences upgraded by Morgan Stanley with a new price targetMorgan Stanley upgraded Gilead Sciences from Equal-Weight to Overweight and set a new price target of $113.00 from $87.00 previously
- Gilead Sciences upgraded by Leerink Partners with a new price targetLeerink Partners upgraded Gilead Sciences from Market Perform to Outperform and set a new price target of $96.00 from $74.00 previously
- Gilead Sciences upgraded by Wells Fargo with a new price targetWells Fargo upgraded Gilead Sciences from Equal Weight to Overweight and set a new price target of $100.00 from $78.00 previously
- Gilead Sciences upgraded by Raymond James with a new price targetRaymond James upgraded Gilead Sciences from Mkt Perform to Outperform and set a new price target of $93.00
- Gilead Sciences upgraded by HSBC Securities with a new price targetHSBC Securities upgraded Gilead Sciences from Reduce to Hold and set a new price target of $69.00
- Gilead Sciences upgraded by BofA Securities with a new price targetBofA Securities upgraded Gilead Sciences from Neutral to Buy and set a new price target of $95.00 from $88.00 previously
- Gilead Sciences upgraded by BMO Capital Markets with a new price targetBMO Capital Markets upgraded Gilead Sciences from Market Perform to Outperform and set a new price target of $100.00 from $90.00 previously
- Gilead Sciences upgraded by Barclays with a new price targetBarclays upgraded Gilead Sciences from Underweight to Equal Weight and set a new price target of $76.00 from $60.00 previously
- Gilead Sciences upgraded by Truist with a new price targetTruist upgraded Gilead Sciences from Hold to Buy and set a new price target of $91.00 from $76.00 previously
- Gilead Sciences upgraded by Piper Sandler with a new price targetPiper Sandler upgraded Gilead Sciences from Neutral to Overweight and set a new price target of $96.00 from $76.00 previously
- Gilead Sciences upgraded by JP Morgan with a new price targetJP Morgan upgraded Gilead Sciences from Neutral to Overweight and set a new price target of $80.00 from $72.00 previously
- Gilead Sciences upgraded by Argus Research with a new price targetArgus Research upgraded Gilead Sciences from Hold to Buy and set a new price target of $75.00
- Gilead Sciences upgraded by ArgusArgus upgraded Gilead Sciences from Hold to Buy
- Gilead Sciences upgraded by BMO Capital Markets with a new price targetBMO Capital Markets upgraded Gilead Sciences from Market Perform to Outperform and set a new price target of $85.00 from $72.00 previously
- Gilead Sciences upgraded by Bernstein with a new price targetBernstein upgraded Gilead Sciences from Mkt Perform to Outperform and set a new price target of $80.00
- Gilead Sciences upgraded by RedburnRedburn upgraded Gilead Sciences from Neutral to Buy